Gland Pharma has entered into a strategic Manufacturing and Supply Agreement (MSA) with a leading global pharmaceutical company to manufacture and supply a portfolio of sterile injectable products for global markets. The partnership establishes the Hyderabad-based firm as an integrated end-to-end partner, covering technology transfer, process development, scale-up, validation, commercial manufacturing, and long-term supply under a full-service Contract Development and Manufacturing Organization (CDMO) model. This agreement provides significant long-term business visibility, with annualized revenue potential estimated at USD 90–100 million once all products are commercialized.

The filing was made pursuant to Regulation 30 read with Part A of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Additional details were provided under SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. The counterparty's name remains undisclosed due to confidentiality obligations, though it is identified as one of the leading global pharmaceutical companies.

Deal Structure and Product Portfolio

The agreement encompasses a diversified basket of oncology and non-oncology products in Vial, Lyo, Ampoules, and pre-filled syringe (PFS) presentations. These formulations cover both complex and conventional injectable types. Gland Pharma will leverage its integrated capabilities across development, technology transfer, manufacturing, quality, and regulatory support to provide a comprehensive "one-stop" solution. The current scope includes 55 Stock Keeping Units (SKUs) to be manufactured across three sites, with provisions to add more products in the near future.

Timeline and Execution

Technology transfer activities are planned for completion within two years. Revenues from this partnership are anticipated to commence from calendar year 2029. The collaboration supports multiple products across various stages of the product lifecycle, including both commercially marketed products and pipeline products under development. Srinivas Sadu, Executive Chairman of Gland Pharma, stated that the partnership highlights the confidence global pharmaceutical companies place in the company's development, technology transfer, manufacturing, and supply capabilities. He noted that the agreement supports the expansion of the CDMO business and creates a strong foundation for future growth.

What the Numbers Show

The commitment to 55 SKUs across three manufacturing sites indicates a substantial allocation of capacity and resources by Gland Pharma. While the revenue generation is deferred until calendar year 2029, the annualized potential of USD 90–100 million represents a significant addition to the company's top-line visibility. The inclusion of both oncology and non-oncology products in complex presentations like pre-filled syringes suggests a focus on high-value, technically demanding formulations rather than conventional low-margin generics. This diversification within the sterile injectables segment aligns with the company's strategy to deepen its integration as a full-service CDMO partner.

Gland Pharma and Neuland Laboratories Limited announced a long-term strategic Contract Development and Manufacturing Organization (CDMO) partnership on August 5, 2026, aimed at expanding sterile Active Pharmaceutical Ingredient (API) manufacturing capabilities. The collaboration addresses rising global demand for sterile APIs used in microparticle depot products by combining Neuland's expertise in complex chemistry with Gland Pharma's established sterile manufacturing infrastructure. This partnership strengthens supply resilience for both innovator and generic pharmaceutical companies seeking reliable sources for complex injectable therapies.

The agreement requires Gland Pharma to establish an additional dedicated sterile manufacturing suite at its JNPC facility in Visakhapatnam. The new facility will be constructed and operated in compliance with current Good Manufacturing Practice (cGMP), USFDA, and EU standards. Designed to support Neuland's growing demand, the suite will provide an integrated solution encompassing development, scale-up, regulatory support, and commercial manufacturing.

Partnership Details

The collaboration leverages the complementary strengths of both entities. Neuland contributes its deep expertise in complex API development, process development, and custom manufacturing, supported by a strong track record of serving global clients. Gland Pharma provides its global sterile manufacturing expertise and proven aseptic manufacturing capabilities. Together, they aim to offer a robust and scalable CDMO solution backed by world-class quality and compliance.

Executive Commentary

Srinivas Sadu, Executive Chairman of Gland Pharma Limited, stated that the investment expands the company's capabilities in sterile API manufacturing and supports increasing customer demand. He emphasized that leveraging the complementary strengths of both organizations allows them to provide a scalable solution backed by manufacturing excellence, creating a foundation for sustainable growth.

Saharsh Davuluri, CEO and Managing Director of Neuland Laboratories Limited, noted that demand for sterile APIs continues to grow as pharmaceutical companies advance increasingly complex injectable therapies. He highlighted that the partnership creates a differentiated platform for global customers, strengthening their ability to deliver the quality, reliability, and supply assurance expected from CDMO partners.

Capacity and Strategic Focus

The addition of approximately 1400 kg of annual capacity represents a targeted expansion rather than a broad infrastructure overhaul. By focusing specifically on microparticle depot products and complex sterile APIs, the partnership signals a strategic shift toward high-value, technically difficult formulations. This specialized capacity addition positions both companies to capture market share in segments where supply resilience and regulatory compliance are critical differentiators, rather than competing on volume alone in standard sterile injectables.